Source: Annual Congress 2013 –New bronchodilators for COPD management
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. H. Ficker, J. A. Wedzicha, M. Decramer, A. FowlerTaylor, P. D'Andrea, C. Arrasate, H. Chen, D. Banerji (Nuernberg, Germany; London, United Kingdom; Leuven, Belgium; East Hanover, United States Of America). QVA149 reduces COPD exacerbation rate in various subgroups of patients: The SPARK study. Eur Respir J 2013; 42: Suppl. 57, 182

Member's Comments

No comment yet.

Related content which might interest you: QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: The SPARK study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Efficacy of roflumilast with concomitant cardiovascular medication in patients with COPD Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management Year: 2013 Once-daily glycopyrronium improves lung function and reduces exacerbations in severe-to-very severe COPD patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 FORWARD: A study of extrafine beclomethasone/formoterol compared with formoterol alone in patients with severe COPD and a history of exacerbations Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Clinically important deterioration in patients with COPD using umeclidinium/vilanterol, tiotropium or placebo: Pooled data Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 A self-treatment programme in patients with COPD: Effectiveness for the reduction of severe exacerbations Source: International Congress 2015 – Latest insights into chronic care Year: 2015 Baseline symptom scores and future risk of severe exacerbation: The SPARK study Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 COPD: Influence of patients’ nutritive status on the exacerbations rate Source: International Congress 2016 – COPD diagnosis and management Year: 2016 Symptom profile of exacerbations in earlier and later COPD Source: Annual Congress 2013 –Asthma and COPD: diseases with different phenotypes Year: 2013 Comparison of COPD patients with high and low symptoms from a real-world US survey Source: International Congress 2015 – Non-inflammatory monitoring of airway diseases Year: 2015 Indacaterol/glycopyrronium (IND/GLY) reduces exacerbations compared with salmeterol/fluticasone (SFC) in various sub-groups from the FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 RT protocol reduces AECOPD readmissions Source: International Congress 2016 – In-patient and out-patient COPD management Year: 2016 The relation of comorbidities with the exacerbation severity in patients with COPD Source: Annual Congress 2013 –COPD mechanisms Year: 2013 Characterization of readmissions in patients hospitalized with COPD exacerbation Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 A global survey conducted to determine frequency of exacerbations in COPD patients Source: Annual Congress 2013 –COPD treatment Year: 2013 Roflumilast added to triple therapy in severe COPD patients with frequent exacerbations: Efficacy and tolerability Source: International Congress 2014 – Markers Year: 2014 Compare clinical effectiveness of various types of bronchodilators in COPD patients Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 Real life assessment of inhaler use and acute exacerbations in 2935 COPD patients Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016